Background

Lipoxins are among a  class of eicosanoids that are derived from arachidonate and known to be prevalent in airway tissues of asthmatics and other lung disease patients. This demonstrates that lipoxins are naturally occurring molecules and closely associated with eosinophil-related pathways. While their exact roles are not fully understood, both Lipoxin A4 (LXA4) and15-Epi-Lipoxin A4 (15-Epi-LXA4) have proven to be involved in anti-inflammatory responses. The LXA4, is however, not effective in abolishing allergen induced eotaxin while the analog 15-Epi-LXA4 has been shown to be effective. Furthermore, the 15-Epi-LXA4 has been established as an inhibitor of eosinophil localization in allergen sensitized tissue making it a molecule of great interest for tissue inflammation studies.

Assay Principle

This ELISA kit was developed to be sensitive and selective for 15-Epi-LXA4 to provide the user a convenient means to study anti-inflammatory responses. The 15-Epi-LXA4 assay kit allows for quantitative results with the ease and convenience of a 96 well format. This assay is a competitive ELISA between enzyme conjugate and 15-Epi-LXA4 for a limited number of binding sites. Our specially designed extraction buffer eliminates the need for most urine and tissue culture supernatant to be extracted. Determination of 15-Epi-LXA4 levels may provide a greater understanding of the pathophysiology of inflammation and other disease.

If using urine as a sample it is recommended to run our

Creatinine Assay kit (CR01)

in conjunction with your samples since urinary creatinine levels may be used to normalize the rate of excretion of other analytes.